Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data

被引:24
作者
In, Haejin [1 ,2 ,3 ,10 ]
Sarkar, Srawani [1 ,3 ]
Ward, Jessica [4 ]
Friedmann, Patricia [1 ,5 ]
Parides, Michael [1 ,5 ,6 ]
Yang, Julie [7 ]
Epplein, Meira [8 ,9 ]
机构
[1] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Surg, Bronx, NY USA
[2] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[4] Albert Einstein Coll Med, Bronx, NY USA
[5] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Cardiothorac & Vasc Surg, Bronx, NY USA
[6] Hosp Special Surg, Res Inst, New York, NY USA
[7] Albert Einstein Coll Med, Montefiore Med Ctr, Div Gastroenterol, Bronx, NY USA
[8] Duke Univ, Duke Canc Inst, Dept Populat Hlth Sci, Durham, NC USA
[9] Duke Univ, Duke Canc Inst, Canc Risk Detect & Intercept Program, Durham, NC USA
[10] Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA
关键词
HELICOBACTER-PYLORI INFECTION; ATROPHIC GASTRITIS; COMBINED ASSAY; IGG ANTIBODY; RISK; MORTALITY; CAGA; POPULATION; METAANALYSIS; PREVALENCE;
D O I
10.1158/1055-9965.EPI-21-1328
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastric cancer lacks specific symptoms, resulting in diagnosis at later stages and high mortality. Serum pepsinogen is a biomarker for atrophic gastritis, a gastric cancer precursor, and may be useful to detect persons at increased risk of gastric cancer. Methods: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was conducted in the United States between 1993 and 2001. ELISA-based pepsinogen tests were conducted on prediagnostic serum samples of 105 PLCO participants who developed gastric cancer and 209 age, sex, and race-matched controls. Pepsinogen positive (PG+) was defined as pepsinogen I & LE; 70 mg/L and pepsinogen I/II ratio & LE;3.0. Results of conditional logistic regression models, and sensitivity and specificity, of PG+ for gastric cancer are reported. Results: Gastric cancer cases were more likely to be PG+ (31.4% vs. 5.5%, P < 0.001) at baseline than controls. Compared to PG-, PG+ was associated with an 8.5-fold increased risk for gastric cancer [95% confidence interval (CI) = 3.8-19.4]. This risk remained significant after adjusting for Helicobacter pylori , family history of gastric cancer, education, smoking, and BMI (aOR, 10.6; 95% CI, 4.3-26.2). In subgroup analysis, PG+ individuals were 11-fold more like to develop non-cardia gastric cancer (OR, 11.1; 95% CI, 4.3-28.8); conversely, they were not significantly more likely to develop cardia gastric cancer (OR, 2.0; 95% CI = 0.3-14.2). PG+ status yielded low sensitivity but high specificity for both noncardia (44.3%; 93.6%) and cardia gastric cancer (5.7%; 97.2%). Conclusions: Prediagnostic serum pepsinogen levels from a large, prospective cohort study were associated with risk of gastric cancer, particularly noncardia gastric cancer. Impact: PG status may identify individuals at higher risk of noncardia gastric cancer for targeted screening or interventions.See related commentary by Zhou and Huang, p. 1257
引用
收藏
页码:1426 / 1432
页数:7
相关论文
共 69 条
[1]   Plasma pepsinogens, antibodies against Helicobacter pylori, and risk of gastric cancer in the Shanghai Women's Health Study Cohort [J].
Abnet, C. C. ;
Zheng, W. ;
Ye, W. ;
Kamangar, F. ;
Ji, B-T ;
Persson, C. ;
Yang, G. ;
Li, H-L ;
Rothman, N. ;
Shu, X-O ;
Gao, Y-T ;
Chow, W-H .
BRITISH JOURNAL OF CANCER, 2011, 104 (09) :1511-1516
[2]   Usefulness of Serum Pepsinogen Levels as a Screening Test For Atrophic Gastritis and Gastric Cancer [J].
Agkoc, Metin ;
Dursun, Hakan ;
Albayrak, Fatih ;
Yilmaz, Omer ;
Kiziltunc, Ahmet ;
Yilmaz, Arif ;
Gundogdu, Cemal .
EURASIAN JOURNAL OF MEDICINE, 2010, 42 (01) :15-18
[3]  
[Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
[4]   Obesity and cancer risk: Emerging biological mechanisms and perspectives [J].
Avgerinos, Konstantinos, I ;
Spyrou, Nikolaos ;
Mantzoros, Christos S. ;
Dalamaga, Maria .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 92 :121-135
[5]   The Serum Pepsinogen Test as a Predictor of Kazakh Gastric Cancer [J].
Cai, Wei Juan ;
Yin, Liang ;
Kang, Qiang ;
Zeng, Zu Chen ;
Wang, Shao Liang ;
Cheng, Jiang .
SCIENTIFIC REPORTS, 2017, 7
[6]   Divergent trends for gastric cancer incidence by anatomical subsite in US adults [J].
Camargo, M. Constanza ;
Anderson, William F. ;
King, Jessica B. ;
Correa, Pelayo ;
Thomas, Cheryll C. ;
Rosenberg, Philip S. ;
Eheman, Christie R. ;
Rabkin, Charles S. .
GUT, 2011, 60 (12) :1644-1649
[7]   Western long-term accuracy of serum pepsinogen-based gastric cancer screening [J].
Castro, Clara ;
Dinis-Ribeiro, Mario ;
Rodrigues, Antonio N. G. ;
Calheiros, Tiago ;
Santos, Joao ;
Pereira, Pedro ;
Ramos, Mariana ;
Cunha, Hugo ;
Andrade, Mara ;
Costa, Anita ;
Sa, Ligia ;
Antunes, Luis ;
Bento, Maria J. ;
Lomba-Viana, Rafael .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (03) :274-277
[8]   Body Mass Index and Risk of Gastric Cancer: A Meta-analysis of a Population with More Than Ten Million from 24 Prospective Studies [J].
Chen, Yi ;
Liu, Lingxiao ;
Wang, Xiaolin ;
Wang, Jianhua ;
Yan, Zhiping ;
Cheng, Jieming ;
Gong, Gaoquan ;
Li, Guoping .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (08) :1395-1408
[9]   Serum Pepsinogen as a Predictor for Gastric Cancer Death A 16-Year Community-based Cohort Study [J].
Chiang, Tsung-Hsien ;
Chiu, Sherry Yueh-Hsia ;
Chen, Sam Li-Sheng ;
Yen, Amy Ming-Fang ;
Fann, Jean Ching-Yuan ;
Liu, Cheng-Ying ;
Chou, Chu-Kuang ;
Chiu, Han-Mo ;
Shun, Chia-Tung ;
Wu, Ming-Shiang ;
Lin, Jaw-Town ;
Lee, Yi-Chia ;
Chen, Tony Hsiu-Hsi ;
Lin, Ming-Wei .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2019, 53 (05) :E186-E193
[10]  
CORREA P, 1994, CANCER RES, V54, pS1941